Display options
Cite
Epstein M, Alvarez PJ, Reaven NL, et al. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2016;22(11):s311-s324
Epstein, M., Alvarez, P. J., Reaven, N. L., Funk, S. E., McGaughey, K. J., Brenner, M. S., Benton, W., & Golestaneh, L. (2016). Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. The American journal of managed care, 22(11), s311-s324.
Epstein, Murray, et al. "Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors." The American journal of managed care vol. 22,11 (2016): s311-s324.
Epstein M, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Brenner MS, Benton W, Golestaneh L. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2016 Aug;22(11):s311-s324. PMID: 27668789.
Copy Download .nbib Format: NLM
Share it on

Am J Manag Care. 2016 Aug;22(11):s311-s324.

Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors.

The American journal of managed care

Murray Epstein, Paula J Alvarez, Nancy L Reaven, Susan E Funk, Karen J McGaughey, Melanie S Brenner, Wade Benton, Ladan Golestaneh

Affiliations

  1. University of Miami Miller School of Medicine, PO Box 016960 (R-126), Miami, FL 33101. E-mail: [email protected].
  2. n.

PMID: 27668789

[No abstract available.]

Publication Types